Dr. Sarah Heilshorn's lab at Stanford University has developed a platform for 3D bioprinting which stiffens the structure post-printing using chemistry that is completely bioorthogonal.
Primary Application Area: Materials, Chemical
Technology Development Status: Concept
Technology Readiness Level: TRL 1
Vetted Programs/Awards: To the best of my knowledge, there is no other awards except the NSF grant.
Organization Type: Academic/Gov Lab
Market Keywords: 3D Bioprinting, Drug Discovery Tissue Models